RxDoctor Payments Data

Edmond Cronin

Clinical Cardiac Electrophysiology · Philadelphia, PANPI 1336454230

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $49,717 of the $72,454 with a category attached, or 68.6%. Medtronic accounts for 97.1% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $39,603, more than ten times the $40 reported in 2019.

$72,454in general payments, 2019–2025

Across 218 payments — averaging $332.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$70K
  • Abbott$869
  • Biosense Webster, Inc.$570
  • Boston Scientific$195
  • Philips North America LLC$184
  • Impulse Dynamics (USA) Inc.$124
  • plus $183 from 3 others
$1,115in research payments, 2019–2025

Across 1 payment — averaging $1115.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Impulse Dynamics (USA) Inc.$1K

What the payments were for

  • Consulting fees$1,3052%
  • Speaking & faculty fees$49,71769%
  • Travel & lodging$15,10621%
  • Food & beverage$6,3269%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,454 in reported general payments places this provider in the 80th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

See all clinical cardiac electrophysiology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$70,016
Medicare patients
293
Services billed
770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$37,415
XareltoRivaroxaban44$28,908
EntrestoSacubitril/Valsartan15$12,314
Flecainide Acetate15$795
Metoprolol Succinate41$565
Amiodarone Hcl13$347
Carvedilol14$171
Furosemide12$85
Paroxetine Hcl11$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$37,41538 claims
Johnson & JohnsonXarelto$100$28,90844 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

Other clinical cardiac electrophysiology in Philadelphia

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →